Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: IRBT stock price vs ECL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ECL's multiple
Needs ECL P/S.
Implied fair value · at IRBT's multiple
Needs Revenue / share, IRBT P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
iROBOT CORPORATION · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
ECOLAB INC. · implied price per share
Bear
$44.93
Base
$57.49
Bull
$73.86
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe IRBT can reverse its revenue decline and restore positive margins and ROIC toward ECL-like quality, then consider the relative valuation case; otherwise, the data supports avoiding IRBT because its profitability, growth, and leverage profile are materially weaker than ECL’s.
On the provided P/S basis, IRBT does not have a usable current trading price, but ECL-implied price is $111.21 versus a narrow valuation range of $107.02, suggesting only limited dispersion around the implied estimate. The gap is not being driven by superior IRBT fundamentals; rather, ECL’s much stronger profitability and balance sheet likely justify a far higher multiple than IRBT.
Supporting Metrics
